Fig. 1: Kaplan–Meier analysis of progression-free survival (a) and overall survival (b) in the HER2-low cohort and HER2-0 cohort. | npj Breast Cancer

Fig. 1: Kaplan–Meier analysis of progression-free survival (a) and overall survival (b) in the HER2-low cohort and HER2-0 cohort.

From: Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Fig. 1

a Median Progression-free Survival (PFS) was 23.6 months (95% CI,18.9-28.1) in the HER2-low cohort and 32.3 months (95% CI, 26.1-NA) in the HER2-0 cohort. b Median Overall Survival (OS) was 48.7 months (95% CI, 42.5-NA) in the HER2-low cohort and 58.3 months (95% CI, 55.7-NA) in the HER2-0 cohort. HER2 human epidermal growth factor receptor 2, CI confidence intervals, PFS progression free survival.

Back to article page